Profession leads direction, mission gathers strength–Tianjin Second People’s Hospital takes care of you

Profession leads direction, mission gathers strength–Tianjin Second People’s Hospital takes care of you


March 18, 2023 is the 23rd “National Liver Love Day”. This year’s publicity theme is “Active Monitoring, Expanding Treatment, and Eliminating the Harm of Hepatitis B”. At present, there are about 86 million cases of chronic hepatitis B virus (HBV) infection in my country. Chronic hepatitis B is still the main liver disease that endangers people’s life and health in my country. We advocate the whole society to take action to popularize the knowledge of hepatitis B prevention and treatment. Actively monitor, standardize diagnosis and treatment, and eliminate the harm of hepatitis B and its complications. In addition to chronic hepatitis B, other chronic liver diseases, such as chronic hepatitis C, autoimmune liver disease, fatty liver disease, drug-induced liver injury and other diseases, will also have diseases along the path of hepatitis, liver fibrosis, liver cirrhosis, and liver cancer. Progress in the same direction also requires great attention and active prevention and control.

Tianjin Second People’s Hospital is a specialized hospital for the diagnosis and treatment of liver diseases. It is a designated hospital for infectious disease medical services in Tianjin. It is a participating unit of the National Infectious Disease Regional Medical Center. Liver and Alcoholic Liver Disease Collaborative Group Unit. The subject of infectious diseases is a key medical construction subject in Tianjin. Department of Hepatology is a national key specialty of traditional Chinese medicine. It has a century of experience in the prevention and treatment of infectious diseases. At the same time, it has formed a full-chain diagnosis and treatment system for the diagnosis of common liver diseases, difficult and rare diseases, the treatment of acute and severe liver diseases, and the management of prognostic diseases, realizing screening, prevention, diagnosis and treatment. unified platform. In December 2019, it became a governing unit of the China Portal Hypertension Alliance, marking that it has been in line with international standards in terms of accurate detection of portal hypertension, early screening, early diagnosis, systematic and standardized treatment, discipline development, and academic research, and is at the domestic leading level.

In 2011, the Tianjin Medical Institute of Liver Diseases was established, which has molecular biology laboratories, medical bioengineering laboratories, pathology laboratories, molecular virology and molecular immunology laboratories, and biological specimen banks that are in line with the international advanced level. At present, the Institute is mainly committed to the basic and clinical research of viral hepatitis, liver cirrhosis, liver cancer, fatty liver, alcoholic liver disease, drug-induced liver disease and autoimmune liver disease, and undertakes major projects of the Ministry of Science and Technology and the National Natural Science Foundation of China, etc. A number of scientific research topics.

The hospital is a pilot hospital that implements the “hepatitis C pay per person” payment model, which facilitates the treatment of chronic hepatitis C patients and reduces the financial burden of patients.

The research on “Clinical Features and Non-invasive Diagnosis of Chronic Hepatitis B Complicated with Non-alcoholic Fatty Liver” led by Professor Mi Yuqiang from the hospital won the second prize of Tianjin Science and Technology Progress Award in 2021, marking that the hospital’s comprehensive treatment level for fatty liver has reached leading.

The treatment of liver diseases with traditional Chinese medicine and integrated traditional Chinese and Western medicine has the domestic first-class diagnosis and treatment technology level. It is a key specialist construction unit of the State Administration of Traditional Chinese Medicine and has Jia Jianwei’s inheritance studio of national famous and veteran Chinese medicine experts.

Relying on the hospital’s powerful full-chain and full-cycle management of liver diseases and patient population, a comprehensive evaluation system has been formed for the latest early diagnosis technology of liver cancer, which has improved the prevention management of “early screening, early diagnosis, and early treatment”, and realized hepatology, interventional Department of Ultrasound Ablation, Department of Liver Surgery, Department of Pathology and other professional expert team (MDT) strategies to formulate the most reasonable, individualized and comprehensive treatment plan for patients, so that patients can obtain the best diagnosis and treatment plan and prognosis. At the same time, the use of precision medical testing to optimize advanced liver cancer molecular targeted therapy and immunotherapy, transjugular intrahepatic portosystemic shunt (TIPS), percutaneous transhepatic gastroesophageal variceal embolization (PTVE) and other mature technologies have improved Prognosis and quality of life in patients with end-stage liver disease.

The Department of Critical Care Medicine is one of the first units in China to carry out artificial liver support treatment, and it is in the leading position in the country in the rescue and treatment of critical illness related to liver failure and other infectious diseases.

Hepatobiliary surgery and tumor surgery are at the domestic advanced level. Radical thyroid cancer surgery under the escort of intraoperative real-time neurological function testing, 3D visualization-assisted splenic aneurysm resection, precise splenectomy, arteriovenous fistula formation, and 3D visualization Advanced surgical diagnosis and treatment technologies such as auxiliary precision liver resection.

The hospital has been engaged in the research and development of liver disease drugs for a long time. Among them, Ligan pills have been used clinically for 44 years; The preparation developed by the hospital in 2008 is used for patients with deficiency of liver, spleen and kidney, and liver cirrhosis, and the curative effect is definite.

The outpatient clinics of the hospital mainly focus on the internal medicine prevention and treatment of liver diseases, including liver disease clinic, fatty liver clinic, liver disease prevention clinic, hepatitis C clinic, traditional Chinese medicine clinic, combined traditional Chinese and Western medicine clinic, and traditional Chinese medicine specialist clinic. At the same time, emergency department, functional examination, anesthesia, ultrasound, imaging, inspection, pharmacy and other specialties are equipped to provide comprehensive treatment guarantee for outpatient and emergency department of liver diseases and inpatients in wards.

Expert introduction

Mi Yuqiang, Yang Jiming, Li Jia, Li Ping, Jia Jianwei, Li Qian, Xu Liang, Liu Feng, Hou Jiancun

Mi Yuqiang

Vice president of Tianjin Second People’s Hospital, second-level chief physician, master tutor. The leader of the internal science (infectious disease) discipline of the key construction discipline of Tianjin Medical Sciences.

Member of the Standing Committee of the Infectious Diseases Branch of the Chinese Medical Association, deputy head of the fatty liver group of the Hepatology Branch of the Chinese Medical Association, and the seventh and eighth chairman of the Infectious Diseases Branch of the Tianjin Medical Association. Established the first fatty liver clinic in Tianjin and the fatty liver diagnosis and treatment center of the National Fatty Liver Health Promotion Project of the Chinese Medical Doctor Association. As the first author to formulate my country’s 2013 “Expert Suggestions on the Standardization of Diagnosis and Treatment of Fatty Liver Diseases”, participated in the formulation of 7 guidelines and expert consensus on infectious diseases and liver diseases in my country, and edited the fatty liver popular science book “Fatty Liver Lecture”. “Chinese Journal of Infectious Diseases”, “Journal of Practical Hepatology”, “Journal of Clinical Hepatobiliary Diseases” and other editorial board members.

Yang Jiming:

Tianjin Famous Doctor, Chief Physician, Professor, Master Tutor

Member of the Hepatology Branch of the Chinese Medical Association, member of the Standing Committee of the Hepatology Branch of the Tianjin Medical Association. “Chinese Journal of Liver Diseases”, “Journal of Clinical Hepatobiliary Diseases” editorial board.

Li Jia

Director of the first and second departments of liver disease, doctor of medicine, doctoral supervisor of Tianjin Medical University and Nankai University, the first Tianjin famous doctor.

Director of Hepatology Branch of Tianjin Medical Association, Executive Director of Infectious Disease Physician Branch of Tianjin Medical Association, Member of Autoimmune Liver Disease Cooperative Group of the 7th Committee of Hepatology Branch of Chinese Medical Association, Autoimmune Liver Disease of Infectious Disease Hospital Management Branch of Chinese Hospital Association Member of the management group, member of the Standing Committee of the Liver Disease Professional Committee of the China Medical Education Association, member of the Second Portal Hypertension Group of the Liver Disease Professional Committee of the Chinese Research Hospital Association, member of the Liver Cancer Internal Medicine Committee of the Chinese Medical Doctor Association, and member of the Public Relations Cooperation Group for Difficult and Severe Liver Diseases . “Journal of Clinical Hepatobiliary Diseases”, “Tianjin Medicine” editorial board.

Li Ping:

Director of Department of Integrated Traditional Chinese and Western Medicine, Chief Physician, Doctor of Medicine, Postdoctoral Fellow in the United States, Master Tutor

Member of the Infectious Disease Prevention and Control Branch of the Chinese Preventive Medicine Association; Member of the Liver Disease (Integrated Traditional Chinese and Western Medicine) Professional Committee of the Chinese Research Hospital Association; He is a member of the Standing Committee of the Society of Hepatology; a member of the Standing Committee of the Digestive Disease Society of Tianjin Society of Integrative Medicine; a member of the Hepatology Society of Tianjin Medical Association; a member of the Hepatobiliary Tumor Professional Committee of Tianjin Anticancer Association. Reviewer of “Journal of Clinical Hepatobiliary Diseases” and “Tianjin Medicine”, reviewer of “European Journal of Clinical Nutrition” and “Open Life Sciences”.

Jia Jianwei

  

Director of Department of Traditional Chinese Medicine, Chief Physician, Master Tutor

Famous Chinese medicine practitioners in Tianjin; Instructor of the sixth batch of famous old Chinese physicians in the country; Vice chairman of the Hepatobiliary Disease Branch of the Chinese Association of Traditional Chinese Medicine; Standing member of the Infectious Diseases Branch of the Chinese Association of Traditional Chinese Medicine; Tianjin TCM health care expert. “Journal of Integrative Traditional Chinese and Western Medicine Hepatology”, “Journal of Clinical Hepatobiliary Diseases” editorial board.

Li Qian:

Director of the Department of Critical Care Medicine, Chief Physician, Master Tutor.

Member of Tianjin Medical Association Intensive Medicine Branch, member of Management Committee of Association of Integrative Traditional Chinese and Western Medicine, member of Tianjin Integrative Medicine Infectious Disease Branch, member of Tianjin Blood Purification Quality Control Center, member of National Artificial Liver Cooperation Group, etc.

Xu Liang:

Hepatology Department Director, Chief Physician.

Member of the Tumor and Liver Disease Professional Committee of the Chinese Anti-Cancer Association, member of the Youth Group of the 12th Committee of the Infectious Diseases Branch of the Chinese Medical Association, member of the Second Chronic Disease Branch of the Chinese Medical and Biological Association, and the first member of the Liver Disease Professional Committee of the Chinese Research Hospital Association Member of Liver and Alcoholic Hepatology Group, Youth Committee of Hepatobiliary Disease Branch of China Association of Traditional Chinese Medicine, Member and Secretary of the Eighth Committee of Infectious Disease Branch of Tianjin Medical Association, Second Session of Clinical Epidemiology and Evidence-Based Medicine Branch of Tianjin Medical Association Deputy Chairman of the Committee, Vice Chairman of the Tumor Translational Medicine Committee of Tianjin Anti-Cancer Association, member of the Liver and Gallbladder Tumor Committee of Tianjin Anti-Cancer Association, leader of the Youth Committee of the Sixth Committee of Hepatology Branch of Tianjin Association of Integrative Traditional Chinese and Western Medicine, Tianjin He is a member of the Society of Traditional Chinese Medicine Liver Diseases, a member of the editorial board of “Journal of Practical Hepatology”, a corresponding editorial board member of “Chinese Journal of Infectious Diseases”, an editorial board member of “TMR Modern Herbal Medicine”, and a reviewer of “Infectious Diseases & Immunity”.

Liu Feng:

Deputy Director of the Fourth Department of Hepatology, Doctor of Medicine, Master Tutor.

Member of the 6th and 7th Youth Committee of the Chinese Medical Association Hepatology Branch; member of the Tianjin Medical Association Infectious Diseases Branch; reviewer of the National Natural Science Foundation of China; editorial board member of the Chinese Journal of Liver Diseases; reviewers of several core journals and SCI journals expert.

Hou Jiancun:

Director of surgery, doctor of medicine, postgraduate tutor.

He is a member of the Liver Committee of Tianjin Anti-Cancer Association, a member of Pancreas Committee of Tianjin Anti-Cancer Association, a member of Infectious Diseases Branch of Tianjin Medical Association, a member of Tianjin Surgical Blood Transfusion Committee, and a member of Metastatic Liver Cancer Treatment Committee of Beijing Cancer Prevention and Treatment Society.



Source link